Evaxion Biotech A/S (NASDAQ:EVAX) Issues Quarterly Earnings Results

Evaxion Biotech A/S (NASDAQ:EVAX) posted its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.19, Zacks reports.

Evaxion Biotech A/S Trading Up 5.1 %

Shares of EVAX stock opened at $1.85 on Tuesday. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The firm has a market cap of $2.17 million, a P/E ratio of -1.28 and a beta of -0.25. The company has a 50 day moving average of $2.46 and a 200-day moving average of $7.07. Evaxion Biotech A/S has a 12-month low of $1.67 and a 12-month high of $22.05.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Lake Street Capital dropped their price target on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Evaxion Biotech A/S in a research note on Thursday, February 20th.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.